Author: Benzinga Newsdesk | November 12, 2025 07:03am
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 26.83 percent. This is a 14.29 percent increase over losses of $(0.14) per share from the same period last year.